Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data

References

• Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531. doi:10.1016/S0140-6736(16)00576-627140670
   PubMed Web of Science ®Google Scholar
• Registre français de la mucoviscidose. Bilan des données 2016 [French CF Registry. Data Report 2016]. Vaincre la Mucoviscidose et Institut national d’études démographiques (Ined) Paris, décembre 2017. Vaincre la Mucoviscidose. 2015 Available from: https://www.vaincrelamuco.org/face-la-mucoviscidose/registre-et-muco-en-chiffres. Accessed February 1, 2018. French.
   Google Scholar
• Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91–96. doi:10.1016/j.jcf.2008.09.00718952504
   PubMed Web of Science ®Google Scholar
• Chin M, Aaron SD, Bell SC. The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. Presse Médicale. 2017;46(6):e139–64. doi:10.1016/j.lpm.2016.11.030
   PubMed Web of Science ®Google Scholar
• Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Médicale. 2017;46(6):e125–38.
   PubMed Web of Science ®Google Scholar
• O’Donohoe R, Fullen BM. Adherence of subjects with cystic fibrosis to their home program: a systematic review. Respir Care. 2014;59(11):1731–1746.25233386
   PubMed Web of Science ®Google Scholar
• Narayanan S, Mainz JG, Gala S, Tabori H, Grossoehme D. Adherence to therapies in cystic fibrosis: a targeted literature review. Expert Rev Respir Med. 2017;11(2):129–145.28107795
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med. 2011;11:5.21251275
   PubMed Web of Science ®Google Scholar
• Nasr SZ, Chou W, Villa KF, Chang E, Broder MS. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. J Med Econ. 2013;16(6):801–808.23506540
   PubMedGoogle Scholar
• Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146(1):142–151. doi:10.1378/chest.13-192624480974
   PubMed Web of Science ®Google Scholar
• Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10(4):258–264. doi:10.1016/j.jcf.2011.03.00521458391
   PubMed Web of Science ®Google Scholar
• Eakin MN, Riekert KA. The impact of medication adherence on lung health outcomes in cystic fibrosis. Curr Opin Pulm Med. 2013;19(6):687–691. doi:10.1097/MCP.0b013e3283659f4524060982
   PubMed Web of Science ®Google Scholar
• Balfour L, Armstrong M, Holly C, et al. Development and psychometric validation of a cystic fibrosis knowledge scale. Respirology. 2014;19(8):1209–1214. doi:10.1111/resp.1237925208592
   PubMed Web of Science ®Google Scholar
• Feiten TDS, Flores JS, Farias BL, et al. Respiratory therapy: a problem among children and adolescents with cystic fibrosis. J Bras Pneumol. 2016;42(1):29–34. doi:10.1590/S1806-3756201600000006826982038
   PubMed Web of Science ®Google Scholar
• Fender P, Weill A. [Epidemiology, public health and medical rates databases]. Rev Epidemiol Sante Publique. 2004;52(2):113–117. doi:10.1016/S0398-7620(04)99032-315138390
   PubMed Web of Science ®Google Scholar
• Adherence to Long-term Therapies: Evidence for Action. World Health Organisation Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed August 22, 2018.
   Google Scholar
• Monégat M, Sermet C, Perronnin M, Rococo E. La polymédication : définitions, mesures et enjeux. Revue de la littérature et tests de mesure [Polypharmacy: definitions, measurement and stakes involved Review of the literature and measurement tests]. Questions d’économie de la santé : 2014 (état de santé, protection sociale, enquête, analyses économiques, comparaisons internationales) - IRDES. irdes. Available from: http://www.irdes.fr/recherche/2014/questions-d-economie-de-la-sante.html#n204. Accessed September 10, 2018. French.
   Google Scholar
• Vollmer WM, Xu M, Feldstein A, Smith D, Waterbury A, Rand C. Comparison of pharmacy-based measures of medication adherence. BMC Health Serv Res. 2012;12:155. doi:10.1186/1472-6963-12-15522691240
   PubMed Web of Science ®Google Scholar
• Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros. 2006;5(3):177–185. doi:10.1016/j.jcf.2006.03.00216679071
   PubMed Web of Science ®Google Scholar
• Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications: new taxonomy for adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi:10.1111/j.1365-2125.2012.04167.x22486599
   PubMed Web of Science ®Google Scholar
• Dima AL, Dediu D. Computation of adherence to medication and visualization of medication histories in R with AdhereR: towards transparent and reproducible use of electronic healthcare data. PLoS One. 2017;12(4):e0174426. doi:10.1371/journal.pone.017442628445530
   PubMed Web of Science ®Google Scholar
• Pednekar P, Malmenas M, Ágh T, Bennett B, Peterson A. Measuring Multiple Medication Adherence–Which Measure When?ISPOR | International Society For Pharmacoeconomics and Outcomes Research Available from: https://www.ispor.org/publications/journals/value-outcomes-spotlight/abstract/november-december-2017/measuring-multiple-medication-adherence-which-measure-when. Accessed August 27, 2018.
   Google Scholar
• R Core Team. R: A Language and Environment for Statistical Computing [internet]. Vienna, Austria: R Foundation for Statistical Computing; 2013 Available from: https://www.r-project.org/. Accessed March 8, 2019.
   Google Scholar
• Faint NR, Staton JM, Stick SM, Foster JM, Schultz A. Investigating self-efficacy, disease knowledge and adherence to treatment in adolescents with cystic fibrosis: adherence in cystic fibrosis treatment. J Paediatr Child Health. 2017;53(5):488–493. doi:10.1111/jpc.2017.53.issue-528186386
   PubMed Web of Science ®Google Scholar
• Dziuban EJ, Saab-Abazeed L, Chaudhry SR, Streetman DS, Nasr SZ. Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol. 2010;45(5):450–458. doi:10.1002/(ISSN)1099-049620425852
   PubMed Web of Science ®Google Scholar
• White H, Shaw N, Denman S, Pollard K, Wynne S, Peckham DG. Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis. Eur Respir J. 2017;49:3. doi:10.1183/13993003.00987-2016
   Web of Science ®Google Scholar
• Keyte R, Egan H, Jackson C, Nash E, Regan A, Mantzios M. A weekend/weekday comparison of adherence to daily treatment regimens in adults with cystic fibrosis. Health Psychol Rep. 2018;6(2):146–157.
   Web of Science ®Google Scholar
• Dodd ME, Webb AK. Understanding non-compliance with treatment in adults with cystic fibrosis. J R Soc Med. 2000;93(Suppl 38):2–8.10911812
   PubMed Web of Science ®Google Scholar
• Smith S, Edwards CT. Long-acting inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2017;19(12):CD012102.
   Google Scholar
• Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros. 2014;13(6):692–698. doi:10.1016/j.jcf.2014.04.00424815094
   PubMed Web of Science ®Google Scholar
• Lin -AH-A, Kendrick J, Wilcox PG, Quon BS. Patient knowledge and pulmonary medication adherence in adult patients with cystic fibrosis. Patient Prefer Adherence. 2017;11:691–698. doi:10.2147/PPA.S13479228408806
   PubMed Web of Science ®Google Scholar
• Blasi F, Carnovale V, Cimino G, et al. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: the FREE study. Respir Med. 2018;138:88–94. doi:10.1016/j.rmed.2018.03.03429724399
   PubMed Web of Science ®Google Scholar
• Dempster NR, Wildman BG, Masterson TL, Omlor GJ. Understanding treatment adherence with the health belief model in children with cystic fibrosis. Health Educ Behav. 2018;45(3):435–443. doi:10.1177/109019811773634629025281
   PubMed Web of Science ®Google Scholar
• Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest. 2011;140(2):425–432. doi:10.1378/chest.11-040121330381
   PubMed Web of Science ®Google Scholar
• Bakker EM, Volpi S, Salonini E, et al. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J. 2011;38(6):1328–1335. doi:10.1183/09031936.0000621121737560
   PubMed Web of Science ®Google Scholar
• McCormack P, Southern KW, McNamara PS. New nebulizer technology to monitor adherence and nebulizer performance in cystic fibrosis. J Aerosol Med Pulm Drug Deliv. 2012;25(6):307–309. doi:10.1089/jamp.2011.093422856641
   PubMed Web of Science ®Google Scholar
• Ball R, Southern KW, McCormack P, Duff AJA, Brownlee KG, McNamara PS. Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time. J Cyst Fibros. 2013;12(5):440–444. doi:10.1016/j.jcf.2012.11.01423369661
   PubMed Web of Science ®Google Scholar
• Siracusa CM, Ryan J, Burns L, et al. Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor. J Cyst Fibros. 2015;14(5):621–626. doi:10.1016/j.jcf.2015.05.00526074007
   PubMed Web of Science ®Google Scholar
• Barker DH, Quittner AL. Parental depression and pancreatic enzymes adherence in children with cystic fibrosis. Pediatrics. 2016;137(2):e20152296. doi:10.1542/peds.2015-229626738883
   PubMed Web of Science ®Google Scholar